The RPL7A antibody targets the ribosomal protein L7A, a component of the 60S ribosomal subunit involved in protein synthesis. Encoded by the *RPL7A* gene (located on chromosome 19q13.2 in humans), this highly conserved protein plays dual roles in ribosome assembly and extraribosomal functions, including potential involvement in cell cycle regulation, apoptosis, and interactions with RNA or other proteins like p53. RPL7A is ubiquitously expressed across tissues, reflecting its essential role in cellular homeostasis. Antibodies against RPL7A are widely used in research to study its expression, localization, and interactions in normal and disease contexts, such as cancer, where ribosomal proteins may exhibit dysregulated expression. These antibodies are validated for techniques like Western blotting, immunofluorescence, and immunoprecipitation, often with cross-reactivity in common model organisms (e.g., mice, rats). Studies using RPL7A antibodies have also explored its potential as a biomarker or therapeutic target, given its links to tumor progression and chemoresistance. Proper validation, including knockdown controls and species specificity checks, is critical due to its homology with other ribosomal proteins.